The Buzz Surrounding Americann Inc. (OTCQB: ACAN)

AmeriCann’s goal is to serve medical cannabis patients by providing state of the art facilities designed and built to produce  consistent medicine that is cultivated and processed in a controlled, secure, and sustainable environment. The company believes in sustainable cultivation and processing practices — and responsibility towards our community and environment — is driven by the core belief that every patient should have access to safe, regulated medical cannabis.

AmeriCann develops world-class facilities for the production of medical cannabis. The Company has a multi-market growth strategy with a current portfolio of over 1,000,000 square feet of sustainable cannabis production infrastructure in development.

Investor Recap

AmeriCann Releases Designs for 345,000 Square Foot Building at Massachusetts Cannabis Manufacturing and Cultivation Project

AmeriCann, Inc. (OTCQB: ACAN), an agricultural-technology company that is developing the next generation of eco-friendly start-of-the-art greenhouse cannabis cultivation and processing properties, has released designs for Building 2 which includes 345,000 square feet of cannabis manufacturing and cultivation infrastructure at its 52-acre Massachusetts Medical Cannabis Center (MMCC) in Freetown, MA.

The configuration of Building 2 includes over 100,000 square feet of dedicated cannabis extraction, processing and product manufacturing space and approx. 245,000 sq. ft. of cultivation infrastructure. The dedicated cultivation facilities are designed to utilize AmeriCann’s proprietary greenhouse system called Cannopy. The design of Building 2 of the MMCC, which is 345,000 square feet, will include three distinct units: 
• Unit A: 184,720 square foot cannabis cultivation facility 
• Unit B: 40,178 square foot extraction and product manufacturing facility; and 
• Unit C: 118,580 square foot cannabis cultivation facility cannabis

AmeriCann will own and operate Unit B which is designed to provide extraction and product manufacturing support to the entire MMCC project, as well as to other licensed cannabis farmers throughout Massachusetts. In addition to large-scale extraction of cannabis plant material, AmeriCann plans to produce branded consumer packaged goods including cannabis beverages, vaporizer products, edible products, non-edible products and concentrates at the state-of-the-art facility.

The Company has already commenced construction on the first phase of the 1 million square foot multi-phase MMCC project with a 30,000 square foot cultivation facility.

AmeriCann plans to replicate the brands, technology and innovations developed at its MMCC project to new markets as a multi-state licensed operator.

Infused products are becoming an increasingly larger segment of total cannabis sales in regulated markets. According to the Wall Street Journal, “Interest in cannabis as an ingredient in food and drinks in on an upswing; beer brewing giant Constellation Brands, Inc. (NYSE: STZ) recently took a $4 billion stake in Canadian marijuana grower Canopy Growth Corp., (NYSE: CPG) which makes cannabis infused drinks and other products.”

Industry experts believe that the pending Massachusetts adult-use market, in conjunction with its existing medical program will exceed $1 billion by 2020. As the first approved adult-use cannabis market on the Eastern US, Massachusetts has the potential to become the epicenter for cannabis innovation and research.

AmeriCann To Operate Large-Scale Cannabis Product Manufacturing Facility in MassachusettsPress Release

AmeriCann, Inc. (OTCQB: ACAN), an agricultural-technology company that is developing the next generation of eco-friendly start-of-the-art greenhouse cannabis cultivation and processing properties, has announced plans to own and operate a large-scale cannabis manufacturing and processing facility at its 52-acre Massachusetts Medical Cannabis Center (MMCC) in Freetown, MA. 

The company has commenced construction on the first phase of the MMCC and recently released designs for the second phase. The second phase includes AmeriCann’s manufacturing facility which is designed to provide support to the entire MMCC project, as well as to other licensed cannabis cultivators throughout Massachusetts.

“Participating directly as an operator allows us to have a larger impact and greater flexibility in meeting consumer and patient demand throughout the country,” said Tim Keogh, CEO of AmeriCann.

AmeriCann’s manufacturing facility is designed to produce branded consumer packaged goods including cannabis beverages, vaporizer products, edible products, non-edible products and concentrates at the state-of-the-art facility.

The company plans to replicate the brands, technology and innovations developed at its MMCC project to new markets as a multi-state operator.

Infused products are becoming an increasingly larger segment of total cannabis sales in regulated markets. According to the Wall Street Journal, “Interest in cannabis as an ingredient in food and drinks in on an upswing; beer brewing giant Constellation Brands, Inc. (NYSE: STZ) recently took a $4 billion stake in Canadian marijuana grower Canopy Growth Corp., (NYSE: CPG) which makes cannabis infused drinks and other products.”

“In Colorado, consumers purchased 12.2 million marijuana infused products in 2017, stated Ben Barton, CFO of AmeriCann. “AmeriCann’s advanced processing and production facility in Massachusetts should play a large role in meeting similar levels of cannabis consumer’s needs in Massachusetts for a consistent supply of a variety of trusted, reliable branded products.”

Industry experts believe that the pending Massachusetts adult-use market, in conjunction with its existing medical program will exceed $1 billion by 2020. As the first approved adult-use cannabis market on the Eastern US, Massachusetts has the potential to become the epicenter for cannabis innovation and research.

AmeriCann CEO to Present at Science and Education Conference in Massachusetts

AmeriCann, Inc. (OTCQB: ACAN), an Agricultural-Technology company that is developing state-of-the-art greenhouse cannabis cultivation and processing properties, announced today that CEO Tim Keogh will be speaking at the Cannabis Community Care and Research Network’s (C3RN) Cannabis Science and Education Series on Sunday, September 23 in Boston, MA.

The event is part of C3RN’s monthly Cannabis Science, Education, and Networking series in Massachusetts to showcase the latest cannabis innovations. The events attract diverse groups of leaders from within and outside of the cannabis industry, public health and policy experts and other businesses. Mr. Keogh will be leading a discussion about best practices for cannabis cultivation and extraction.

Tim Keogh, AmeriCann CEO, has spoken at cannabis industry conferences across the United States as an expert on topics including industry best practices, real estate development and the cannabis economy. Marijuana Business Daily recognized Mr. Keogh as one of the “Top People to Watch in 2018.”

AmeriCann is developing the Massachusetts Medical Cannabis Center (MMCC), a state-of-the-art cannabis cultivation and processing development in the midst of the rapidly growing Massachusetts medical cannabis market. The MMCC project is approved for 1 million square feet, which will be developed in phases and is expected to be one of the most technologically advanced cultivation facilities in the nation.

On September 25, 2018, AmeriCann will host a ground-breaking celebration at the MMCC in Freetown at 11am. The event will celebrate the first phase of the MMCC construction which will be a 30,000 sq. ft. cannabis cultivation, processing and research facility. AmeriCann plans to complete the first phase of the MMCC by the spring of 2019.

AmeriCann to Host Ground Breaking Celebration for the Massachusetts Medical Cannabis Center on Tuesday, September 25

AmeriCann, Inc. (OTCQB: ACAN), an agricultural-technology company that is developing the next generation of eco-friendly start-of-the-art greenhouse cannabis cultivation and processing properties, plans to host a ground breaking celebration for its Massachusetts Medical Cannabis Center (MMCC) on Tuesday, September 25.

AmeriCann designed the MMCC on a 52-acre parcel located in Freetown, Mass. The project allows for 987,000 sq. ft. of cannabis cultivation and processing infrastructure and will be developed in three phases. The ground breaking event will celebrate the first phase of the MMCC construction which will be a 30,000 sq. ft. cannabis cultivation, processing and research facility. AmeriCann plans to complete the first phase of the MMCC by the spring of 2019. Campanelli Construction is the general contractor and CBRE/New England is the project manager for the MMCC.

The first phase of the MMCC project consists of 30,000 sq. ft. of cultivation, processing and research facilities.

“We believe the first of phase will set new standards for the industry and have a big impact for the company moving forward,” stated AmeriCann Founder Ben Barton. “The ground breaking signifies the first step in creating a sustainable process to produce clean, quality cannabis.”

AmeriCann uses greenhouse technology, which is superior to the current industry standard of growing cannabis in warehouse facilities under artificial lights. According to industry experts, by capturing natural sunlight, greenhouses use 25 percent fewer light bulbs, and utility bills are up to 75 percent less than in typical warehouse cultivation facilities. As such, AmeriCann’s Cannopy System enables cannabis to be produced with a greatly reduced carbon footprint, making the final product less expensive. Additionally, greenhouse construction costs are nearly half of warehouse construction costs.

The MMCC will be built to maximize workflow and take advantage of growing plants under natural sunlight which the Company believes produces healthier plants from both cannabinoid and terpene perspectives, making the final product higher in quality.

“Currently, almost all the cannabis being produced in Massachusetts is from converted warehouses with 100 percent artificial light, high energy costs and huge carbon footprints,” said Tim Keogh, AmeriCann’s Chief Executive Officer. “The MMCC facility is designed to produce superior sun grown cannabis products year-round in a controlled environment at a lower cost. This is the first phase of an extensive project designed to help the Massachusetts cannabis industry reach its full potential.”

AmeriCann assists partners to obtain licenses and cultivate medicine in its next generation of eco-friendly state-of-the-art cannabis cultivation facilities and provides essential resources including access to a team of experts, and capital, which has been traditionally hard to obtain for cannabis companies. The first publicly traded Certified B Corp in the cannabis industry, AmeriCann has proven its commitment to sustainable, clean cultivation of medical cannabis.

AmeriCann Engages Award Winning Public Relations Firm

AmeriCann, Inc. (OTCQB: ACAN), an agricultural-technology company that is developing the next generation of eco-friendly state-of-the-art greenhouse cannabis cultivation and processing properties, announced today that it has engaged Teak Media + Communication to support the Company’s public relations programs.

Teak Media + Communication will deploy a comprehensive communications program aimed at increasing awareness of AmeriCann and its accomplishments.

“Teak Media’s track record of success in increasing awareness for public companies is impressive,” stated AmeriCann founder Ben Barton. “Additionally, Teak Media is uniquely qualified to communicate our vision, as we share a common set of values for social and environmental standards.”

AmeriCann and Teak Media are both certified B Corps – for-profit companies certified by the nonprofit BLab to meet rigorous standards of social and environmental performance, accountability, and transparency.

“The burgeoning cannabis industry needs AmeriCann,” says Jackie Herskovitz Russell, President and Founder of Teak Media. “We are inspired by the company’s mission to cultivate cleaner and more sustainable cannabis. We are encouraged by the prospect of more environmentally sustainable medicine made from marijuana. We are grateful to be on the AmeriCann team and are excited to help the company succeed.”

Barton added that, “While Teak Media is developing a national strategy for AmeriCann, one major strength of the firm is that with Teak Media being headquartered in Boston, its team has an in-depth understanding of the local market of our flagship project in Massachusetts.”

AmeriCann is developing the Massachusetts Medical Cannabis Center (MMCC), a cannabis cultivation and processing development in the heart of the rapidly growing Massachusetts medical cannabis market. The MMCC project is approved for 1 million square feet, which will be developed in phases and is expected to be one of the most technologically advanced cultivation facilities in the nation.

In 2015, AmeriCann saw that Massachusetts did not have enough cultivation and processing infrastructure in planning or development. With that knowledge, AmeriCann designed, permitted, and now controls a 52-acre parcel of land. AmeriCann secured entitlements for 987,000 square feet of cannabis cultivation and processing infrastructure. Reports of product shortages in the Massachusetts market are beginning to surface in mainstream media such as the Boston Globe and Marijuana Business Daily. The lengthy design, permitting and cannabis licensing process in Massachusetts creates a significant barrier for new projects entering the market.

“Almost all the cannabis being produced in Massachusetts is from converted warehouses with 100% artificial light, high energy costs and huge carbon footprints,” said Tim Keogh, AmeriCann’s Chief Executive Officer. “Our purpose-built facilities can produce superior sun grown cannabis products year-round in a controlled environment at a lower cost and with a far less carbon footprint than warehouse growers. This is the first phase of an extensive project designed to help the Massachusetts cannabis industry reach its full potential.”

The Commonwealth of Massachusetts has begun awarding licenses to businesses that will provide cannabis access to consumers over 21 years of age in addition to the existing medical cannabis market. Industry experts believe it will become the epicenter for cannabis innovation and research for the entire northeast US with annual sales of over $1.2 billion by 2021.

15 Comments
  1. Yuena L. 3 weeks ago
    Reply

    when cannabis finally becomes legal on a full federal scale, the cannabis market will be realized and many opioids will be replaced. Big Pharma is scared shitless of this.

    • Mike Hart 2 weeks ago
      Reply

      Medical cannabis should be covered. Patients should not have to resort to more harmful medications (codeine) that are covered. The lack of medical cannabis coverage has significantly contributed to the opioid crisis. #covermedicalcannabis

      • Eran Cohen 6 days ago
        Reply

        Opioid prescriptions will plummet once cannabis is introduced.

  2. Sameepa Shetty 3 weeks ago
    Reply

    How will cannabis cultivation change in the future? How large is the cannabis market in Massachussetts?

  3. Brantley 3 weeks ago
    Reply

    The demand for medical cannabis is huge. There is a huge market for this company.

    • Von Klein 1 week ago
      Reply

      As of March 2018, there were more than 295,000 medical cannabis patients in the system across Canada. With October 17th fast approaching, it’s time to examine.

      • Gregory Jewell 7 days ago
        Reply

        my only fear is that once Cannabis is legal on a nation-wide scale that there will still be many restrictions on specific cannabis products

        • Gary Gordon 5 days ago
          Reply

          Studies have shown that medical cannabis can be used as a muscle relaxant. It’s clear that controlling leg cramps and muscle spasms at the molecular level are just one of the many potential uses of CBD in the medical world

          • David Welker 4 days ago

            CBD and medical cannabis help me with the anger issues I’m almost never angry I’m still depressed and irritated but at least I’m not angry all the time #ptsdsucks

  4. Todd Sonoga 2 weeks ago
    Reply

    Volume and price movement today is interesting. With this momentum we may head back over $3.50

  5. Silvia Grey 6 days ago
    Reply

    The designs for the Massachusetts facility is impressive, how will the cultivated cannabis be distributed?

    • Jonah 6 days ago
      Reply

      i think distribution channels are very important. A good distribution channel will help increase company’s sales.

  6. Nicholas 4 days ago
    Reply

    I hope NJ will pass the cannabis legalization.

    • Joshua Wall 3 days ago
      Reply

      The United States may potentially #Legalize medical cannabis on a federal level. This is great news, as many Americans have had to relocate in order to gain access to #MedicalCannabis.

      • Cristian 3 days ago
        Reply

        I don’t think it will be legalized in a federal level. But it will be legal in the state level.

Leave a Comment

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Americann Inc. financial and corporate news dissemination, FinancialBuzz.com has been compensated thirty thousand dollars by axiom group. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com .